This is an injectable that stops the production of testosterone, thus there is not much of a waiting time. The concept is a surge that produces a very large amount of testosterone which in essence shuts down the future production of the hormone in the body. 
It was approved in December 2008 but not known when it will be available.
Degarelix is the new injectable treatment for patients with advanced prostate cancer, a killer of 28,000 men last year. Developed by Ferring Pharmaceuticals, degarelix blocks the hormone testosterone that feeds prostate cancer cells.
The number-one priority for prostate cancer patients is to stop the body's testosterone production because the hormone helps the cancer grow. Testosterone is like a running back and degarelix is the defensive line. It shuts testosterone production down—hard and fast.This treatment stimulates an extremely large amount of testosterone production in a few days—an overproduction that causes the body to automatically stop generating testosterone.
A major concern with this treatment (called luteinizing hormone releasing hormone agonist) is that some patients with advanced prostate cancer might not survive the initial hormone surge.
0 comments :
Post a Comment